TY - JOUR
T1 - Mailing abortion pills does not delay care
T2 - A cohort study comparing mailed to in-person dispensing of abortion medications in the United States
AU - Koenig, Leah R.
AU - Raymond, Elizabeth G.
AU - Gold, Marji
AU - Boraas, Christy M.
AU - Kaneshiro, Bliss
AU - Winikoff, Beverly
AU - Coplon, Leah
AU - Upadhyay, Ushma D.
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/5
Y1 - 2023/5
N2 - Objective: Given the substantial barriers to abortion access in the United States, many clinics now mail patients abortion medications. We examined whether dispensing the medications by mail prolonged time to medication use. Study design: We analyzed data from no-test medication abortions with medication provided either by mail or in a clinic from 11 United States clinics from February 2020 to January 2021. We examined mean number of days from patients’ first contact with the clinic to mifepristone ingestion, its two-component intervals (first contact to medication dispensing and dispensing to mifepristone ingestion), and pregnancy duration at mifepristone ingestion. We used Poisson regression to compare mean outcomes across three dispensing methods: in-person, mailed from the clinic, and mailed from a mail-order pharmacy. Results: Among the 2600 records, patients took mifepristone on average at 49 days of gestation (95% CI, 47–51) and 7 days (95% CI, 4–10) after first contact. Mean time from first contact to mifepristone ingestion was 6 days when medications were dispensed in-person and 9 days when mailed (p = 0.38). While time from first contact to dispensing was similar across methods (6 days in-person, 5 days mailed, p = 0.77), more time elapsed from dispensing to mifepristone ingestion when medications were mailed (4 days from clinic, 5 days from mail-order pharmacy) versus dispensed in-person (0.3 days, p < 0.001). Time to mifepristone ingestion was shorter with higher pregnancy duration. Pregnancy duration at ingestion was similar across methods (48 days in-person, 50 days mailed). Conclusions: Mailing medications did not significantly prolong time from patients’ first contact with the clinic to mifepristone ingestion or increase pregnancy duration at mifepristone ingestion. Implications: Abortion providers should offer a range of medication abortion dispensing options, prioritizing patient preference.
AB - Objective: Given the substantial barriers to abortion access in the United States, many clinics now mail patients abortion medications. We examined whether dispensing the medications by mail prolonged time to medication use. Study design: We analyzed data from no-test medication abortions with medication provided either by mail or in a clinic from 11 United States clinics from February 2020 to January 2021. We examined mean number of days from patients’ first contact with the clinic to mifepristone ingestion, its two-component intervals (first contact to medication dispensing and dispensing to mifepristone ingestion), and pregnancy duration at mifepristone ingestion. We used Poisson regression to compare mean outcomes across three dispensing methods: in-person, mailed from the clinic, and mailed from a mail-order pharmacy. Results: Among the 2600 records, patients took mifepristone on average at 49 days of gestation (95% CI, 47–51) and 7 days (95% CI, 4–10) after first contact. Mean time from first contact to mifepristone ingestion was 6 days when medications were dispensed in-person and 9 days when mailed (p = 0.38). While time from first contact to dispensing was similar across methods (6 days in-person, 5 days mailed, p = 0.77), more time elapsed from dispensing to mifepristone ingestion when medications were mailed (4 days from clinic, 5 days from mail-order pharmacy) versus dispensed in-person (0.3 days, p < 0.001). Time to mifepristone ingestion was shorter with higher pregnancy duration. Pregnancy duration at ingestion was similar across methods (48 days in-person, 50 days mailed). Conclusions: Mailing medications did not significantly prolong time from patients’ first contact with the clinic to mifepristone ingestion or increase pregnancy duration at mifepristone ingestion. Implications: Abortion providers should offer a range of medication abortion dispensing options, prioritizing patient preference.
KW - Mailing
KW - Medication abortion
KW - Mifepristone
KW - Pharmacy
KW - Risk Evaluation and Mitigation Strategy (REMS)
KW - Telehealth
UR - http://www.scopus.com/inward/record.url?scp=85150055434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150055434&partnerID=8YFLogxK
U2 - 10.1016/j.contraception.2023.109962
DO - 10.1016/j.contraception.2023.109962
M3 - Article
C2 - 36736715
AN - SCOPUS:85150055434
SN - 0010-7824
VL - 121
JO - Contraception
JF - Contraception
M1 - 109962
ER -